WATERTOWN, Mass.--(BUSINESS WIRE)--
pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), an emerging specialty
pharmaceutical company and leader in developing sustained release, drug
delivery products for treatment of back-of-the-eye diseases, today
announced that its President and CEO, Dr. Paul Ashton, will present at
the 15th Annual BioCEO & Investor Conference, being held at
the Waldorf-Astoria Hotel in New York, Monday and Tuesday, February 11
and 12. Dr. Ashton will make his presentation on Tuesday, February 12 at
1 p.m. EST. A webcast of the presentation will be available at:
http://www.veracast.com/webcasts/bio/ceoinvestor2013/19217378.cfm
or at the company's website: www.psivida.com.
There will be a webcast replay available one hour after the conclusion
of Dr. Ashton's presentation that day and it will be available until May
12, 2013.
About pSivida Corp.
pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drugs designed to be released at a controlled and steady rate
for months or years. pSivida is currently focused on treatment of
chronic diseases of the back of the eye utilizing its core technology
systems, Durasert™ and BioSilicon™. Two FDA-approved products,
Vitrasert™ and Retisert™ are licensed to Bausch & Lomb. The company has
licensed ILUVIEN® for DME to Alimera Sciences and that product has
received marketing authorization in Austria, France, Germany, Portugal,
Spain and the UK. pSivida has clinical trials ongoing for the treatment
of posterior uveitis and glaucoma and hypertension. Other technologies
under development by pSivida include protein and antibody delivery
systems in early clinical stages.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995: Various statements made in this release are
forward-looking, and are inherently subject to risks, uncertainties and
potentially inaccurate assumptions. All statements that address
activities, events or developments that we intend, expect or believe may
occur in the future are forward-looking statements. The following are
some of the factors that could cause actual results to differ materially
from the anticipated results or other expectations expressed,
anticipated or implied in our forward-looking statements: uncertainties
with respect to: Alimera's ability to finance, achieve additional
marketing approvals, successfully commercialize and achieve market
acceptance of, and generate revenues to pSivida from, ILUVIEN for DME in
the EU; outcome of reimbursement for ILUVIEN in the U.K., Alimera's
resubmission of its NDA for ILUVIEN for DME and its ability to obtain
regulatory approval for, and if approved, to finance, successfully
commercialize and achieve market acceptance of, and generate revenues to
pSivida from, ILUVIEN for DME in the U.S.; financing and success of
Phase III posterior uveitis trials including efficacy, side effects and
risk/benefit profile of the posterior uveitis micro-insert; initiation,
financing and success of Latanoprost Product Phase II trials and
exercise by Pfizer of its option; development of products using Tethadur
and BioSilicon; initiation and completion of clinical trials and
obtaining regulatory approval of product candidates; adverse side
effects; ability to attain profitability; ability to obtain additional
capital; further impairment of intangible assets; fluctuations in
operating results; decline in royalty revenues; ability to, and to find
partners to, develop and market products; termination of license
agreements; competition and other developments affecting sales of
products; market acceptance; protection of intellectual property and
avoiding intellectual property infringement; retention of key personnel;
product liability; consolidation in the pharmaceutical and biotechnology
industries; compliance with environmental laws; manufacturing risks;
risks and costs of international business operations; credit and
financial market conditions; legislative or regulatory changes;
volatility of stock price; possible dilution; possible influence by
Pfizer; absence of dividends; and other factors described in our filings
with the SEC. Given these uncertainties, readers are cautioned not to
place undue reliance on such forward-looking statements. Our
forward-looking statements speak only as of the dates on which they are
made. We do not undertake any obligation to publicly update or revise
our forward-looking statements even if experience or future changes
makes it clear that any projected results expressed or implied in such
statements will not be realized.
IN US:
Beverly Jedynak, President, Martin E. Janis & Company, Inc.
312-943-1123
773-350-5793
(cell)
bjedynak@janispr.com
IN
AUSTRALIA:
Brian Leedman, Vice President, Investor Relations,
pSivida Corp.
+61 (0) 41 228 1780
brianl@psivida.com
Source: pSivida
News Provided by Acquire Media
